Goldman Sachs CEO Solomon: Current M&A activity is 20% lower than the ten-year average.

Goldman Sachs CEO Solomon: There is no doubt that there have been some changes in consumer behavior.

Market News: Securities and Exchange Board of India is about to release documents on futures and options trading.

S&P Global (SPGI.N): Expects to execute additional accelerated share repurchase (ASR) program totaling $1.5 billion in the coming weeks.

Turkish Central Bank: Rental inflation risk is expected to continue for a long time.

The UK Competition and Markets Authority (CMA): It is investigating Alphabet’s partnership with artificial intelligence startup Anthropic PBC.

Paypal (PYPL.O) shares rose 2% in premarket trading after it raised its annual profit forecast.

Turkish Central Bank: Energy prices are expected to rise significantly in July.

Turkish Central Bank: The increase in underlying inflation is expected to be relatively limited.

Turkish Central Bank: Leading indicators show that monthly inflation will temporarily rise in July.

PayPal (PYPL.O) expects full-year free cash flow of about $6 billion, up from its previous forecast of about $5 billion.

Paypal (PYPL.O) reported adjusted earnings per share of $1.19 in the second quarter, compared with the market estimate of $1.00.

Procter & Gamble (PG.N) reported a 2% increase in organic sales for its Fabric and Home Care division in the fourth quarter, compared with market expectations for a 3.85% increase.

Procter & Gamble (PG.N) reported fourth-quarter net sales of $20.53 billion, compared with market expectations of $20.74 billion.

Pfizer (PFE.N) shares rose more than 3% in pre-market trading as its second-quarter results beat expectations.

Pfizer (PFE.N) expects operating income growth to reach 9%-11% in 2024; previously expected to be 8%-10%.

Pfizer (PFE.N) expects full-year adjusted earnings per share of $2.45 to $2.65; it previously expected $2.15 to $2.35.

Pfizer (PFE.N) reported adjusted earnings per share of $0.60 in the second quarter, compared with the market estimate of $0.46.

Pfizer (PFE.N): Expects to achieve at least $4 billion in net cost savings by the end of 2024.